Joel Picus

8PUBLICATIONS
94CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente

|Mar 05, 2025
A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma.

Sumanta K Pal, Alice Bernard-Tessier, Peter Grell

|Aug 08, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).

Maha Hussain, Masha Kocherginsky, Neeraj Agarwal

|Jan 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).

Rahul Aggarwal, Glenn Heller, David W Hillman

|Oct 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.

Daniel P Petrylak, Bernhard J Eigl, Saby George

|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Jonathan E Rosenberg, Karla A Ballman, Susan Halabi

Pageof 2

Frequent Collaborators

3 joint publications

Susan Halabi

3 joint publications

Michael J Morris

3 joint publications

Scott Tagawa

2 joint publications

Leonard J Appleman